Company news
Milestone Pharmaceuticals Inc. news in 2026
Milestone Pharmaceuticals Inc.'s news releases, calls and decks from 2026, newest first.
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 3, 2026
Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026
November 3, 2026
New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation
November 2, 2026
Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences
October 19, 2026
Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
October 9, 2026
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
September 3, 2026
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
September 2, 2026
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes
August 27, 2026
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
August 21, 2026
Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026
Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026
August 4, 2026
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 2, 2026
July 6, 2026
Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026
May 6, 2026
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST Nasal Spray in Patients with PSVT
April 13, 2026
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST (etripamil) Nasal Spray in Patients with PSVT
April 13, 2026
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT
April 9, 2026
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
April 7, 2026
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies
March 30, 2026
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT
March 20, 2026
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session
March 16, 2026
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
March 12, 2026
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
February 26, 2026
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer
February 10, 2026
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 3, 2026
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
January 26, 2026
Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency
January 6, 2026
Calls in 2026
Decks in 2026
- Q2 2026 Earnings Presentation
Earnings · 22 slides · Aug 12, 2026